These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32639668)

  • 1. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.
    Ito K; Murotani K; Kubo A; Kunii E; Taniguchi H; Shindoh J; Asada K; Imaizumi K; Takahashi K; Karayama M; Okuno M; Inui N; Hataji O; Morikawa S; Hayai S; Suda T; Abe T; Tsuda T; Yamagichi T; Kimura T; Oya Y; Yoshida T; Hida T
    Cancer Sci; 2020 Oct; 111(10):3705-3713. PubMed ID: 32639668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in
    Girard N; Moro-Sibilot D; Bouée S; Emery C; Torreton E; Le Lay K; Luciani L; Maritaz C; Chouaid C
    Future Oncol; 2020 Jun; 16(16):1115-1124. PubMed ID: 32352321
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
    Arrieta O; Catalán R; Guzmán-Vazquez S; Barrón F; Lara-Mejía L; Soto-Molina H; Ramos-Ramírez M; Flores-Estrada D; de la Garza J
    BMC Cancer; 2020 Sep; 20(1):829. PubMed ID: 32873256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G
    JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
    Su VY; Yang KY; Huang TY; Hsu CC; Chen YM; Yen JC; Chou YC; Chang YL; He CH
    Sci Rep; 2020 Sep; 10(1):14965. PubMed ID: 32917914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
    Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
    Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.
    Ito K; Morise M; Wakuda K; Hataji O; Shimokawaji T; Takahashi K; Furuya N; Takeyama Y; Goto Y; Abe T; Kato T; Ozone S; Ikeda S; Kogure Y; Yokoyama T; Kimura M; Yoshioka H; Murotani K; Kondo M; Saka H
    ESMO Open; 2021 Jun; 6(3):100115. PubMed ID: 33984681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
    Chang HC; Huang KT; Tseng CC; Chen YM; Lai CH; Chang YP; Chen YC; Chuang HY; Wang CC
    Thorac Cancer; 2023 Nov; 14(32):3217-3225. PubMed ID: 37704454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
    Bilgin B; Sendur MAN; Yucel S; Celik E; Ozyukseler DT; Ayhan M; Basoglu T; Ilhan A; Akdeniz N; Gulmez A; Dogan I; Aktas BY; Gurbuz M; Koca S; Paydas S; Tatli AM; Cinkir HY; Alan O; Erol C; Hizal M; Kut E; Menevse S; Sakalar T; Taskaynatan H; Deniz GI; Karaagac M; Avci O; Sen E; Karatas F; Akinci MB; Dede DS; Demir A; Demirkazık A; Oksuzoglu B; Kilickap S; Yumuk F; Yalcin B
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2145-2152. PubMed ID: 33433657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer.
    Byun JY; Han S; Qdaisat A; Park C
    Expert Opin Drug Saf; 2024 Aug; 23(8):1007-1015. PubMed ID: 38088244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
    Lau SC; Chooback N; Ho C; Melosky B
    Clin Lung Cancer; 2019 Sep; 20(5):e576-e583. PubMed ID: 31178389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
    Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    JAMA Oncol; 2018 Aug; 4(8):1112-1115. PubMed ID: 29327061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
    Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R
    Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.